Trial Profile
A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Balixafortide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Polyphor
- 22 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Aug 2011 New trial record